Literature DB >> 21837801

Antibody response and avidity of respiratory syncytial virus-specific total IgG, IgG1, and IgG3 in young children.

G R O Freitas1, D A O Silva, J Yokosawa, N T Paula, L F Costa, B M Carneiro, L Z G Ribeiro, T F M Oliveira, J R Mineo, D A O Queiróz.   

Abstract

Respiratory syncytial virus (RSV) is a major cause of acute respiratory disease in infants and young children. Considering that several aspects of the humoral immune response to RSV infection remain unclear, this study aimed to investigate the occurrence, levels, and avidity of total IgG, IgG1, and IgG3 antibodies against RSV in serum samples from children ≤5 years old. In addition, a possible association between antibody avidity and severity of illness was examined. The occurrence and levels of RSV-specific IgG depended on age, with infants <3 months old displaying high levels of antibodies, which were probably acquired from the mother. Children ≥24 months old also showed frequent occurrence and high levels of IgG, which was produced actively during infection. In addition, the avidity assay showed that the avidity of RSV-specific total IgG and IgG1 was lower in infants <3 months old who had acute respiratory disease than in age-matched controls. The avidity of RSV-specific IgG detected in children ≥24 months old with lower respiratory infection was lower than that in children with upper respiratory infection. These results indicate that the presence of high avidity RSV-specific IgG antibodies may lead to better protection against RSV infection in children <3 months old, who may have a lower probability of developing disease of increased severity. In addition, children ≥24 months old with RSV-specific IgG antibodies of low avidity tended to develop more severe RSV illness. These findings may be helpful in establishing vaccination schedules when a vaccine becomes available.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837801     DOI: 10.1002/jmv.22134

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

Review 1.  Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity.

Authors:  Jop Jans; Marloes Vissers; Jacco G M Heldens; Marien I de Jonge; Ofer Levy; Gerben Ferwerda
Journal:  Rev Med Virol       Date:  2013-11-14       Impact factor: 6.989

2.  Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.

Authors:  Cristina Capella; Supranee Chaiwatpongsakorn; Erin Gorrell; Zachary A Risch; Fang Ye; Sara E Mertz; Sara M Johnson; Melissa Moore-Clingenpeel; Octavio Ramilo; Asuncion Mejias; Mark E Peeples
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

Review 3.  The Human Immune Response to Respiratory Syncytial Virus Infection.

Authors:  Clark D Russell; Stefan A Unger; Marc Walton; Jürgen Schwarze
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

4.  A Recombinant BCG Vaccine Is Safe and Immunogenic in Neonatal Calves and Reduces the Clinical Disease Caused by the Respiratory Syncytial Virus.

Authors:  Fabián E Díaz; Mariana Guerra-Maupome; Paiton O McDonald; Daniela Rivera-Pérez; Alexis M Kalergis; Jodi L McGill
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

5.  Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age.

Authors:  Jop Jans; Oliver Wicht; Ivy Widjaja; Inge M L Ahout; Ronald de Groot; Teun Guichelaar; Willem Luytjes; Marien I de Jonge; Cornelis A M de Haan; Gerben Ferwerda
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

Review 6.  New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.

Authors:  Nicolás M S Gálvez; Jorge A Soto; Alexis M Kalergis
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

7.  Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.

Authors:  Nao Jounai; Megumi Yoshioka; Miyuki Tozuka; Kazue Inoue; Tatsuya Oka; Kazuki Miyaji; Katsuyasu Ishida; Naoki Kawai; Hideyuki Ikematsu; Chiaki Kawakami; Hiroyuki Shimizu; Masaaki Mori; Ken J Ishii; Fumihiko Takeshita
Journal:  EBioMedicine       Date:  2017-01-16       Impact factor: 8.143

8.  Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf.

Authors:  Jodi L McGill; Sean M Kelly; Pankaj Kumar; Savannah Speckhart; Shannon L Haughney; Jamie Henningson; Balaji Narasimhan; Randy E Sacco
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

9.  In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.

Authors:  Elisabeth A van Erp; Puck B van Kasteren; Teun Guichelaar; Inge M L Ahout; Cornelis A M de Haan; Willem Luytjes; Gerben Ferwerda; Oliver Wicht
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

10.  Recombinant BCG Vaccines Reduce Pneumovirus-Caused Airway Pathology by Inducing Protective Humoral Immunity.

Authors:  Jorge A Soto; Nicolás M S Gálvez; Claudia A Rivera; Christian E Palavecino; Pablo F Céspedes; Emma Rey-Jurado; Susan M Bueno; Alexis M Kalergis
Journal:  Front Immunol       Date:  2018-12-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.